Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Relacorilant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892174/0/en/Corcept-Therapeutics-Announces-Presentations-of-Results-of-Pivotal-Phase-3-GRACE-Trial-Evaluating-Relacorilant-in-Patients-with-Hypercortisolism-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Corcept: GRACE Trial Met Primary Endpoint In Cushing's Syndrome
    Corcept: GRACE Trial Met Primary Endpoint In Cushing's Syndrome

    28 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/28/2888977/0/en/Corcept-Announces-Primary-Endpoint-Met-in-Pivotal-Phase-3-GRACE-Trial-of-Relacorilant-in-Patients-With-Hypercortisolism-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    28 May 2024
    Share Share
    Corcept Completes Enrollment in Pivotal Ph 3 Trial of Relacorilant
    Corcept Completes Enrollment in Pivotal Ph 3 Trial of Relacorilant

    08 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/08/2859131/0/en/Corcept-Completes-Enrollment-in-Pivotal-Phase-3-Rosella-Trial-of-Relacorilant-in-Patients-With-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    08 Apr 2024
    Share Share
    Corcept Completes Enrollment in Ph 3 Trial of Relacorilant in ACS
    Corcept Completes Enrollment in Ph 3 Trial of Relacorilant in ACS

    01 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/01/2855141/0/en/Corcept-Completes-Enrollment-in-Phase-3-Gradient-Trial-of-Relacorilant-in-Patients-With-Adrenal-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share
    Corcept Therapeutics to Start PIII Trial of Relacorilant Plus Nab-Paclitaxel
    Corcept Therapeutics to Start PIII Trial of Relacorilant Plus Nab-Paclitaxel

    06 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/06/2456669/0/en/Corcept-Therapeutics-to-Start-Phase-3-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-in-Patients-With-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    06 Jun 2022
    Share Share
    Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Ovarian Cancer
    Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Ovarian Cancer

    30 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/30/2413251/0/en/Relacorilant-Plus-Nab-Paclitaxel-Extends-Survival-in-Women-with-Recurrent-Platinum-resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    30 Mar 2022
    Share Share